BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 22047054)

  • 1. A novel class of small molecule inhibitors of HDAC6.
    Inks ES; Josey BJ; Jesinkey SR; Chou CJ
    ACS Chem Biol; 2012 Feb; 7(2):331-9. PubMed ID: 22047054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
    Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
    Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovative Strategies for Selective Inhibition of Histone Deacetylases.
    Maolanon AR; Madsen AS; Olsen CA
    Cell Chem Biol; 2016 Jul; 23(7):759-768. PubMed ID: 27447046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
    Christianson DW
    Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities.
    Zhang L; Zhang Y; Chou CJ; Inks ES; Wang X; Li X; Hou J; Xu W
    ChemMedChem; 2014 Mar; 9(3):638-48. PubMed ID: 24227760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
    Krieger V; Hamacher A; Gertzen CGW; Senger J; Zwinderman MRH; Marek M; Romier C; Dekker FJ; Kurz T; Jung M; Gohlke H; Kassack MU; Hansen FK
    J Med Chem; 2017 Jul; 60(13):5493-5506. PubMed ID: 28574690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a histone deacetylase 6 inhibitor and its biological effects.
    Lee JH; Mahendran A; Yao Y; Ngo L; Venta-Perez G; Choy ML; Kim N; Ham WS; Breslow R; Marks PA
    Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15704-9. PubMed ID: 24023063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model.
    Routholla G; Pulya S; Patel T; Adhikari N; Abdul Amin S; Paul M; Bhagavatula S; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Dec; 117():105446. PubMed ID: 34717237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation.
    Ashwini N; Garg M; Mohan CD; Fuchs JE; Rangappa S; Anusha S; Swaroop TR; Rakesh KS; Kanojia D; Madan V; Bender A; Koeffler HP; Basappa ; Rangappa KS
    Bioorg Med Chem; 2015 Sep; 23(18):6157-65. PubMed ID: 26299825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis and Biological Evaluation of a Phenyl Butyric Acid Derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 Inhibitor with Anti-proliferative Activity on Cervix Cancer and Leukemia Cells.
    Rodríguez-Fonseca RA; Sixto-López Y; Fragoso-Vázquez MJ; Flores-Mejía R; Cabrera-Pérez LC; Vázquez-Moctezuma I; Rosales-Hernández MC; Bello M; Martínez-Archundia M; Trujillo-Ferrara JG; Becerra-Martínez E; Correa-Basurto J
    Anticancer Agents Med Chem; 2017; 17(10):1441-1454. PubMed ID: 28044941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue.
    Jha S; Kim JH; Kim M; Nguyen AH; Ali KH; Gupta SK; Park SY; Ha E; Seo YH
    Eur J Med Chem; 2024 Feb; 265():116057. PubMed ID: 38142511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
    Brush MH; Guardiola A; Connor JH; Yao TP; Shenolikar S
    J Biol Chem; 2004 Feb; 279(9):7685-91. PubMed ID: 14670976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
    De Vreese R; D'hooghe M
    Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.
    Gaisina IN; Tueckmantel W; Ugolkov A; Shen S; Hoffen J; Dubrovskyi O; Mazar A; Schoon RA; Billadeau D; Kozikowski AP
    ChemMedChem; 2016 Jan; 11(1):81-92. PubMed ID: 26592932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
    Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
    Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.